PuraPharm Corporation Limited (1498.HK)
HKD 0.55
(-3.51%)
HKD 0.55
(-3.51%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 377.54 Million HKD | -4.69% |
| 2022 | 396.14 Million HKD | -11.36% |
| 2021 | 446.9 Million HKD | 12.39% |
| 2020 | 397.65 Million HKD | -11.32% |
| 2019 | 448.4 Million HKD | 1.09% |
| 2018 | 443.59 Million HKD | -3.82% |
| 2017 | 461.21 Million HKD | 788.34% |
| 2016 | 51.91 Million HKD | 148.61% |
| 2015 | -106.81 Million HKD | -178.56% |
| 2014 | 135.95 Million HKD | -12.48% |
| 2013 | 155.33 Million HKD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 354.87 Million HKD | 3.22% |
| 2023 Q2 | 372.22 Million HKD | -6.04% |
| 2023 FY | 377.54 Million HKD | -4.69% |
| 2023 Q4 | 377.54 Million HKD | 1.43% |
| 2022 FY | 396.14 Million HKD | -11.36% |
| 2022 Q4 | 396.14 Million HKD | -0.8% |
| 2022 Q2 | 399.32 Million HKD | -10.65% |
| 2021 FY | 446.9 Million HKD | 12.39% |
| 2021 Q4 | 446.9 Million HKD | 5.16% |
| 2021 Q2 | 424.95 Million HKD | 6.87% |
| 2020 Q4 | 397.65 Million HKD | 21.41% |
| 2020 Q2 | 327.52 Million HKD | -26.96% |
| 2020 FY | 397.65 Million HKD | -11.32% |
| 2019 FY | 448.4 Million HKD | 1.09% |
| 2019 Q4 | 448.4 Million HKD | -10.99% |
| 2019 Q2 | 503.75 Million HKD | 13.56% |
| 2018 Q4 | 443.59 Million HKD | -0.25% |
| 2018 FY | 443.59 Million HKD | -3.82% |
| 2018 Q2 | 444.68 Million HKD | -3.58% |
| 2017 FY | 461.21 Million HKD | 788.34% |
| 2017 Q4 | 461.21 Million HKD | 21.11% |
| 2017 Q2 | 380.83 Million HKD | 633.51% |
| 2016 Q4 | 51.91 Million HKD | 977.38% |
| 2016 FY | 51.91 Million HKD | 148.61% |
| 2016 Q2 | 4.81 Million HKD | 104.51% |
| 2015 FY | -106.81 Million HKD | -178.56% |
| 2015 Q4 | -106.81 Million HKD | -160.17% |
| 2015 Q2 | 177.52 Million HKD | 30.58% |
| 2014 FY | 135.95 Million HKD | -12.48% |
| 2014 Q4 | 135.95 Million HKD | 0.0% |
| 2013 FY | 155.33 Million HKD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 245.939% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 81.419% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | -6251.766% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | -25.209% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 2083.134% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | -1119.946% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 272.217% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | -47.386% |
| SSY Group Limited | 1.71 Billion HKD | 77.967% |
| JBM (Healthcare) Limited | -7.39 Million HKD | 5202.703% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | -11.886% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 99.259% |